Agios Pharmaceuticals, Inc. reported a total revenue of $54.0 million for the fiscal year ending December 31, 2025, marking a significant increase from $36.5 million in 2024 and $26.8 million in 2023. The growth in revenue was primarily driven by increased sales of its product PYRUKYND®, which generated $49.2 million in the U.S. and $4.9 million from international markets. The company’s net loss for 2025 was $412.8 million, compared to a net income of $673.7 million in 2024, which was largely attributed to the sale of Vorasidenib Royalty Rights. The accumulated deficit as of December 31, 2025, stood at $561.7 million.
In terms of operational developments, Agios has made significant strides in its product pipeline. The company launched AQVESME™, an FDA-approved treatment for anemia in adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia, in late January 2026. Additionally, Agios is advancing its clinical programs for mitapivat, which is being evaluated for sickle cell disease (SCD) and pediatric patients with PK deficiency. The company also entered into a license agreement with Alnylam Pharmaceuticals in July 2023 for the development of AG-236, a siRNA targeting the TMPRSS6 gene for polycythemia vera.
Agios has expanded its commercial infrastructure to support the launch of AQVESME™ and has entered into distribution agreements with NewBridge Pharmaceuticals and Avanzanite Bioscience for commercialization in the Gulf Cooperation Council (GCC) region and the European Economic Area, respectively. As of December 31, 2025, the company employed 539 full-time staff, with a focus on enhancing its workforce to support ongoing and future commercialization activities.
Looking ahead, Agios anticipates continued investment in research and development, particularly for its product candidates, which may lead to increased operating expenses. The company expects to incur significant costs associated with the commercialization of PYRUKYND® and AQVESME™, as well as ongoing clinical trials for mitapivat and other candidates. Agios has indicated that its existing cash, cash equivalents, and marketable securities, totaling $1.2 billion as of December 31, 2025, will support its operations, but it may need to raise additional capital to fund future growth and development initiatives. The company remains focused on navigating the complexities of regulatory approvals and market acceptance to achieve its long-term goals in the rare disease treatment space.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly in classical hematology. Its lead product, PYRUKYND® (mitapivat), targets hemolytic anemias and is FDA-approved for PK deficiency. With a focus on expanding its portfolio, Agios is advancing treatments for thalassemia and sickle cell disease. The company aims to leverage its expertise in cellular metabolism to address significant unmet medical needs in these areas.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.